Search by Drug Name or NDC

NDC 42239-0001-08 Atovaquone 750 mg/5mL Details

Atovaquone 750 mg/5mL

Atovaquone is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Abon Pharmaceuticals, LLC. The primary component is ATOVAQUONE.

MedlinePlus Drug Summary

Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most likely to affect people with human immunodeficiency virus [HIV]) in teenagers and adults. Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia.

Related Packages: 42239-0001-08
Last Updated: 04/07/2024
MedLinePlus Full Drug Details: Atovaquone

Product Information

NDC	42239-0001
Product ID	42239-001_0aac7935-6b23-773e-e063-6394a90a8f3f
Associated GPIs
GCN Sequence Number	n/a
GCN Sequence Number Description	n/a
HIC3	n/a
HIC3 Description	n/a
GCN	n/a
HICL Sequence Number	n/a
HICL Sequence Number Description	n/a
Brand/Generic	n/a
Proprietary Name	Atovaquone
Proprietary Name Suffix	n/a
Non-Proprietary Name	Atovaquone
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	SUSPENSION
Route	ORAL
Active Ingredient Strength	750
Active Ingredient Units	mg/5mL
Substance Name	ATOVAQUONE
Labeler Name	Abon Pharmaceuticals, LLC
Pharmaceutical Class	Antimalarial [EPC], Antiprotozoal [EPC]
DEA Schedule	n/a
Marketing Category	ANDA
Application Number	ANDA214272
Listing Certified Through	2024-12-31

Package

NDC 42239-0001-08 (42239000108)

Pricing Information	N/A
NDC Package Code	42239-001-08
Billing NDC	42239000108
Package	1 BOTTLE in 1 CARTON (42239-001-08) / 210 mL in 1 BOTTLE
Marketing Start Date	2023-11-14
NDC Exclude Flag	N